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AortaHyperhomocysteinemia, characterized by high plasmahomocysteine levels, is recognized as an independent risk
factor for cardiovascular diseases. The increased synthesis of homocysteine, a product of methioninemetabolism
involving B vitamins, and its slower intracellular utilization cause increased ﬂux into the blood. Plasma homocys-
teine level is an important reﬂection of hepatic methionine metabolism and the rate of processes modiﬁed by B
vitamins aswell as different enzyme activity. Lowering homocysteinemight offer therapeutic beneﬁts. However,
approximately 50% of hyperhomocysteinemic patients due to cystathionine-beta-synthase deﬁciency are bio-
chemically responsive to pharmacological doses of B vitamins. Therefore, effective treatments to reduce homo-
cysteine levels are needed, and gene therapy could provide a novel approach. We recently showed that
hepatic expression of DYRK1A, a serine/threonine kinase, is negatively correlated with plasma homocysteine
levels in cystathionine-beta-synthase deﬁcient mice, a mouse model of hyperhomocysteinemia. Therefore,
Dyrk1a is a good candidate for gene therapy to normalize homocysteine levels. We then used an adenoviral con-
struct designed to restrict expression of DYRK1A to hepatocytes, and found decreased plasma homocysteine
levels after hepatocyte-speciﬁc Dyrk1a gene transfer in hyperhomocysteinemic mice. The elevation of pyridoxal
phosphatewas consistent with the increase in cystathionine-beta-synthase activity. Commensuratewith the de-
creased plasma homocysteine levels, targeted hepatic expression of DYRK1A resulted in elevated plasma
paraoxonase-1 activity and apolipoprotein A-I levels, and rescued the Akt/GSK3 signaling pathways in aorta of
mice, which can prevent homocysteine-induced endothelial dysfunction. These results demonstrate that
hepatocyte-restricted Dyrk1a gene transfer can offer a useful therapeutic targets for the development of new se-
lective homocysteine lowering therapy.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Hyperhomocysteinemia, which results from an elevation of plasma
homocysteine (Hcy) levels, is well recognized as an important risktathionine-β-synthase; DS, Down sy
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[1,2]. Hcy is produced during the intracellular conversion of methionine
via the adenosylated compounds S-adenosylmethionine (SAM) and
S-adenosylhomocysteine (SAH). The process of Hcy synthesis is calledndrome; DYRK1A, dual-speciﬁcity tyrosine-(Y)-phosphorylation regulated kinase-1A;
cell; NQO1, NAD(P)H quinone oxidoreductase-1; PLP, pyridoxal phosphate; PON1,
enosylhomocysteine; SAHH, S-adenosylhomocysteine hydrolase; VEGF, vascular endo-
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groups used in numerous metabolic processes. The metabolism of Hcy
stands at the crossing of two pathways, remethylation, the process
leading to the reconstruction of the methionine particle, and trans-
sulfuration pathway. Once Hcy is formed, it may be recycled to methio-
nine after remethylation by three different pathways. The ﬁrst involves
the B12-dependent enzyme methionine synthase (MS), an enzyme that
uses 5-methyltetrahydrofolate as the methyl donor, which is generated
by 5,10-methylene tetrahydrofolate reductase (MTHFR). The second
pathway involves the enzyme betaine-homocysteine methyltransferase
(BHMT) which uses betaine as the methyl donor [2]. The third pathway
involves BHMT-2 which uses S-methylmethionine and to a lesser extent
SAM as a methyl donor [3]. Hcy may also undergo condensation with
serine to form cystathionine, which is catalyzed by the vitamin B6-
dependent cystathionine-β-synthase (CBS), the ﬁrst enzyme involved in
the trans-sulfuration pathway. Hcy can also turn back to SAH via reversal
of the S-adenosylhomocysteine hydrolase (SAHH) reaction [2].
Hcy is cytotoxic to cells if allowed to accumulate. Impairment of
hepatic Hcy metabolism can lead to higher intracellular concentra-
tions and export to the blood. Hence, plasma Hcy level is an important
reﬂection of hepatic methionine metabolism and of the rate of pro-
cesses modiﬁed by B vitamins. Reduction of Hcy levels is the key
objective in treatment of hyperhomocysteinemia. Vitamin B6 in phar-
macological doses in combination with folic acid or vitamin B12 or
both is the treatment of choice for CBS deﬁciency. However, approx-
imately 50% of hyperhomocysteinemic patients due to CBS deﬁciency
are biochemically responsive to pyridoxine (vitamin B6) [4]. Patients
who are non-pyridoxine responsive are advised to use a methionine
restricted cysteine supplemented died mostly in combination with
some pyridoxine, folic acid and vitamin B12 supplementation. How-
ever, the biochemical control achieved by treatment did not result
in normal levels of circulating Hcy in most patients [5]. Then reduc-
tion of plasma Hcy level by another pathway needs to be explored.
We recently found that the protein level of the serine/threonine ki-
nase Dyrk1a was reduced in liver of CBS-deﬁcient mice, which was
not observed at the gene expression level. Moreover, the use of pri-
mary hepatocytes/Kupffer cells co-culture showed that degradation
of Dyrk1a induced by hyperhomocysteinemia requires calpain activa-
tion [6]. We also demonstrated that Dyrk1a is involved in methionine
metabolism at different crossroads and its hepatic protein expression
is negatively correlation with plasma Hcy level [6,7]. Therefore,
Dyrk1a is a good candidate for gene therapy to normalize Hcy levels.
However, DYRK1A overexpression may contribute to cognitive im-
pairment [8,9]. Moreover, we recently found an increase in DYRK1A
protein expression in brain of Cbs+/−mice [10]. Indeed, the liver con-
stitutes the appropriate target for gene transfer since the liver plays a
central role in the metabolism of methionine and contributes to much
of the plasma Hcy [11,12].
In this study, we used an adenoviral vector to express DYRK1A
speciﬁcally in the liver of hyperhomocysteinemic mice and studied
the effects on hyperhomocysteinemia and associated hepatic and en-
dothelial dysfunction.
2. Materials and methods
2.1. Construction, generation, and production of adenoviral vector
“AdDYRK1A”
The E1E3E4-deleted [13] adenoviral vector “AdDYRK1A” was con-
structed to induce hepatocyte speciﬁc overexpression of DYRK1A. The
2.6 kb rat Dyrk1a cDNA sequence was obtained after restriction with
BglII and AfeI from pEGFP–DYRK1A [14]. To obtain AdDYRK1A, the
Dyrk1a cDNA sequence was ligated into the corresponding sites of
pTG14681–DC172.A-I intron HCR2 [15]. This plasmid contains the
1.2 kb DC172 promoter, consisting of an 890 bp human α1-antitrypsin
promoter and two copies of the 160 bp α1-microglobulin enhancer,upstream of the 5′UTR of the human apo A-I gene that contains the ﬁrst
intron, and 2 copies of the 774 bp hepatic control region-1 (Fig. 1A). Gen-
eration of the E1E3E4-deleted adenoviral vector “AdDYRK1A” and large-
scale vector production were performed as described previously [13].
2.2. Mice, genotyping, and in vivo gene transfer experiments
All procedures were carried out in accordance with internal guide-
lines of the French Agriculture Ministry for animal handling. Mice
were maintained in a controlled environment with unlimited access to
food andwater on a 12 h light/dark cycle. Micewere fed a standard lab-
oratory diet (CRM, Special Diets Services, Dietex, France Usine) given ad
libitum. This diet has a protein content of 19%, a methionine content of
2.700 mg kg−1, a folic acid content of 4.41 mg kg−1 and a vitamin
B12 content of 0.082 mg kg−1. Number ofmice and sufferingweremin-
imized as possible. Mice heterozygous for targeted disruption of the Cbs
gene (Cbs+/−) were generously donated by Dr. N. Maeda (Department
of Pathology, University of North Carolina, Chapel Hill, NC, USA) [16].
Cbs+/− mice, on a C57BL/6 background, were obtained by mating
male Cbs+/−mice with female wild-type C57BL/6 (Cbs+/+) mice. DNA
isolated from 4-week-old mice tails biopsies was subjected to geno-
typing of the targeted Cbs allele using polymerase chain reaction (PCR)
assay [16]. Cbs+/− mice, 3 at 4 months of age, were injected, in the
retro-orbital sinus, with adenoviral vector AdDYRK1A to have 2×1012
adenoviral particles/kg body weight. A concomitant control adenoviral
vector “Adnull” was not used in this study as this control has been
shown to be equivalent to saline buffer [17–20]. Control mice, healthy
control Cbs+/+ mice and diseased control Cbs+/− mice, received an
equivalent dose of saline buffer and were used as references to monitor
hyperhomocysteinemic development. Mice were euthanized 1 or
4 weeks after injection. An equal number of male and female mice
was used for each group.
2.3. Preparation of serum samples, tissue collection, and plasma total Hcy
assay
Upon euthanization, blood samples were obtained by retro-
orbital sinus sampling with heparinized capillaries, collected into
tubes containing a 1/10 volume of 3.8% sodium citrate, and immedi-
ately placed on ice. Plasma was isolated by centrifugation at 2500×g
for 15 min at 4 °C. Liver and spleen were harvested, snap-frozen,
and stored at −80 °C until use. Plasma total Hcy, deﬁned as the
total concentration of Hcy after quantitative reductive cleavage of
all disulﬁde bonds, was assayed using the ﬂuorimetric high-
performance liquid chromatography (HPLC) method as previously
described [21].
2.4. Protein extraction and Slot blot analysis
Liver, aorta and spleen protein extracts were prepared by homog-
enizing tissue in phosphate-buffered saline (PBS) with a cocktail of
proteases inhibitors (1 mM Pefabloc SC, 5 μg/mL E64, and 2.5 μg/mL
Leupeptin). Homogenates were centrifuged at 12,500×g for 15 min
at 4 °C. Supernatants were then assayed for protein concentrations
with the Coomassie (Bradford) Protein Assay reagent (Bio-Rad).
Since speciﬁcity of each primary antibody used has been ﬁrst validat-
ed by western blotting [10]. Protein extracts (40 μg), under reducing
conditions, were subjected to Slot blotting on nitrocellulose transfer
membrane PROTRAN® (Whatman). Membrane was then blocked in
10% nonfat dry milk in Tris–saline buffer (1.5 mM Tris, 5 mM NaCl,
0.1% Tween-20) and probed overnight at 4 °C with an anti-DYRK1A
antibody (1/250) (Abnova Corporation, Tebu, France) or with an
anti-apolipoprotein A-I (apo A-I) antibody (1/1000) (cell signaling,
Ozyme, France) or with a polyclonal anti-CBS antibody (1/10,000)
[22]. Horseradish peroxidase-conjugated secondary antibody and
Western Blotting Luminol Reagent (Santa Cruz Biotechnology, Tebu,
Fig. 1. Overexpression of DYRK1A in liver of CBS-deﬁcient mice, using an adenoviral vector, “AdDYRK1A”. A. Schematic representation of the adenoviral vector used to induce
hepatocyte-speciﬁc overexpression of DYRK1A in CBS-deﬁcient (Cbs+/−) mice. DYRK1A protein expression in liver of wild type (Cbs+/+) mice and Cbs+/− mice uninjected with
AdDYRK1A (B), in liver of Cbs+/− mice one week (C) and four week (D) after injection and in spleen (E) of Cbs+/− mice compared to uninjected mice (Cbs+/−), determined by
Slot blotting. Values were obtained by normalization of images from DYRK1A to total proteins colored with Ponceau-S. Data were normalized to the mean of wild-type mice
(Cbs+/+) or uninjected CBS-deﬁcient (Cbs+/−) mice. n=number of mice.
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immunoblots obtained using an LAS-3000 imaging system (Fugi
Photo Film Co., Ltd.) were used for densitometric measurementswith an image analyzer (UnScan It software, Silk Scientiﬁc Inc.).
Quantiﬁcation of total proteins after Ponceau-S coloration was used
as an internal control.
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Tissue samples from aorta were sheared with two stainless beads
in protein extraction buffer (50 mM Tris pH=6.8, 2% SDS, 5% glycer-
ol, 2 mM DTT, 2.5 mM EDTA, 2.5 mM EGTA, 1× HALT Phosphatase in-
hibitor (Perbio 78420), Protease inhibitor cocktail complete MINI
EDTA-free (ref 1836170, Roche), 2 mM Na3VO4 and 10 mM NaF)
using a Tissue Lyser (Qiagen). Extracts were boiled for 10 min at
100 °C, sonicated to reduce viscosity and centrifuged 10 min at
15,000 rpm. The supernatant is harvested and stored at−80 °C. Pro-
tein concentration is determined (Pierce BCA reducing agent compat-
ible kit, ref 23252). For reverse phase protein array (RPPA), samples
are printed onto nitrocellulose covered slides (Schott Nexterion
NC-C) using a dedicated arrayer (Aushon Biosystems 2470). Slides
are processed using an Autostainer (Dako, Glostrup, Denmark). Brief-
ly, slides are incubated with avidin, biotin and peroxydase blocking
reagents (Dako) before saturation with TBS containing 0.1% Tween-
20 and 5% BSA (TBST–BSA). Slides are then probed overnight at 4 °C
with primary antibodies diluted in TBST–BSA. After washes with
TBST, arrays are probed with horseradish peroxidase-coupled sec-
ondary antibodies (Jackson ImmunoResearch Laboratories) diluted
in TBST–BSA for 1 h at room temperature. To amplify the signal, slides
are incubated with Bio-Rad Ampliﬁcation Reagent for 15 min at room
temperature. The arrays are washed with TBST, probed with
Alexa647-Streptavidin (Molecular Probes) diluted in TBST–BSA for
1 h at room temperature and washed again in TBST. The processed
slides are dried by centrifugation and scanned using a GenePix
4000B microarray scanner (Molecular Devices). Spot intensity was
determined with MicroVigene software (VigeneTech Inc). Normaliza-
tion of the data was performed as previously described [23], using a
negative control slide (no primary antibody) and a total protein
stain. For the latter, arrays are incubated 15 min in 7% acetic acid
and 10% methanol, rinsed twice in water, incubated 10 min in Sypro
Ruby protein blot stain (S11791, Invitrogen) and rinsed again. Used an-
tibodies are: Akt (ref 9272, Cell signaling, Ozyme, France, 1/1000),
phospho-Akt (ser 473) (ref 4058, cell signaling, Ozyme, France, 1/250),
GSK3-alpha-beta (ref sc-7291, Santa Cruz Biotechnology, Tebu, France,
1/500), phospho-GSK3-alpha-beta (ser21-9) (ref 9331, cell signaling,
Ozyme, France, 1/1000), and phospho-GSK3-alpha-beta (Tyr279-216)
(ref 2309–01, Epitomics, CliniSciences, France, 1/500).
2.6. Enzyme activity assays
SAHH activity was measured in the forward hydrolysis direction
following the protocol described by Villanueva and Halsted [24]
with some modiﬁcations. Protein extracts (200 μg) were incubated for
5 min at 37 °C in 1 mL of reaction mixture (452 mM NaCl, 8.9 mM KCl,
33 mM Na2HPO4, 6.6 mM KH2PO4, 0.1% gelatin, 1.2 mM MTT, 1.1 U
adenosine deaminase, 0.45 U nucleoside phosphorylase and 0.1 U
xanthine oxidase). The SAHH reaction was started by adding 80 μM
S-(5′-adenosyl)-L-homocysteine to the mixture. Following 5 min of in-
cubation at 37 °C, SAHH-speciﬁc activity was detected by the production
of formazan, which is detected by measuring the absorbance at 578 nm
using a spectrophotometer (Lambda XLS, PerkinElmer).
NAD(P)H quinone oxidoreductase-1 (NQO1) activity was assayed on
150 μg of protein extracts following the protocol described by Benson et
al. [25]. Proteins were incubated for 8 min at room temperature in PBS
containing 0.07% bovine serum albumin (pH 7.4) and 0.01% Tween-20.
Then, a mixture containing 0.2 mM β-nicotinamide adenine dinucleo-
tide, reduced (NADH), 5 μM ﬂavin adenine dinucleotide (FAD), and
25 mM Tris–HCl (pH 7.4) was added to the protein preparations. Two
conditions were prepared, with or without 10 μM of dicoumarol
(Calbiochem, MERCK) used to speciﬁcally block NQO1. The reaction
was started by adding 40 μM of 2,6-dichlorophenolindophenol (DCPIP).
The reduction of DCPIP was assayed by measuring the absorbance at
600 nm every 30 s for 3 min using a spectrophotometer (Lambda XLS,PerkinElmer). NQO1 activity was determined by subtraction of the activ-
ity recorded in presence of dicoumarol.
CBS activity assaywas performed on 200 μg of protein extracts as de-
scribed previously [26]. Proteins were incubated for 1 h at 37 °C with
1 mM DL-propargylglycine, 0.2 mM pyridoxal 5′-phosphate, 10 mM
L-serine, 10 mM DL-Hcy, and 0.8 mM S-(5′-adenosyl)-L-methionine,
using a DTNB [5,5′-dithiobis-(2-nitrobenzoic acid)] based-assay. The re-
action was performed at 37 °C by measuring the absorbance at 412 nm
over 20 min, using a spectrophotometer (Lambda XLS, PerkinElmer).
Paraoxonase-1 (PON1) activity assay was performed on 100 μg of
liver protein extracts or 5 μL of plasma. PON1 arylesterase activity to-
ward phenyl acetate was quantiﬁed spectrophotometrically using
20 mM Tris–HCl (pH 8.3), 1 mM CaCl2, and 10 mM phenyl acetate.
The reaction was performed at room temperature by measuring the
appearance of phenol at 270 nm every 10 s for 1 min using a spectro-
photometer (Lambda XLS, PerkinElmer).
2.7. Hepatic SAM and SAH concentrations
Levels of SAM and SAH in liver were determined by stable isotope
dilution liquid chromatography–tandem mass spectrometry in an
adapted method from Gellekink et al. [27]. In brief, frozen tissues
were homogenized with ice-cold perchloric acid then centrifuged.
Supernatent cleanup was performed with solid phase extraction
(SPE) columns after neutralization of the acidiﬁed samples. The type
of SPE cartridge used was phenyl boronic acid (SPE Bond Elut–PBA,
100 mg) from Varian (Courtaboeuf, les Ulis, France). Two isotopically
labeled internal standards were used: 13C5-SAH and D3-SAM.
Analytes were detected using the transitions m/z 399–250 (SAM),
402–250 (D3-SAM), 385–136 (SAH), and 390–136 (13C5-SAH) for
quantiﬁcation and the transitions m/z 399–136 (SAM), 402–136
(D3-SAM), 385–134 (SAH), and 390–134 (13C5-SAH) for qualiﬁcation.
The detection limits (signal to noise ratio=3), estimated from the
lower calibration point, were 0.4 nmol/L for SAM and 0.6 nmol/L for
SAH. The variability of the assay expressed as CVs (n=4) were 13.3%
for SAM and 9.6% for SAH with a plasma pool containing 130 nmol/L
of SAM and 11 nmol/L of SAH.
2.8. Hepatic pyridoxal phosphate concentration
The pyridoxal phosphate (PLP) detection assay was previously de-
scribed [28]. Brieﬂy, the high-performance liquid chromatography
(HPLC) systemwas a Shimadzu LC20 series, an autosampler with cooler
set at 4 °C, a columnovenheld at 40 °C, an additional pump (postcolumn
pump) connected to the HPLC system and then after the column with a
T-junction, and a ﬂuorescent detector. The analytical HPLC column is a
BDS Hypersil 5 μm C8 150×4.6 mm (ThermoScientiﬁc). The mobile
phase A was 3.5 mM 1-octanesulfonic acid and 1.2 mM triethylamine
(TEA) in 0.033 M phosphoric acid, adjusted to pH 2.16 with 6 M KOH.
The mobile phase B was ACN. The gradient used consisted of phase A
with increasing amounts of phase B according to the following scheme:
0.5% phase B for 3 min, increase to 10% over 10 min, 10% until 22 min,
increase to 15% over 3 min, 15% until 28 min, decrease over 3 min to
0.5%, and ﬁnally 0.5% phase B until 46 min after injection. The ﬂow rate
was 1.2 mL/min. The postcolumn reagents consisted of 770 mM
K2HPO4 buffer containing 5.26 mM sodium bisulﬁte. The ﬂow rate of
the postcolumn reagentwas 0.3 mL/min. Column eluents were detected
with a ﬂuorescent detector with excitation and emission wavelengths
set at 328 and 393 nm, respectively.
2.9. Plasma apolipoprotein A-I protein levels
Plasma apo A-I protein levels was measured by ELISA (E90519M,
Uscn, Life Science Inc.) according to manufacturer's instructions.
After the development of the colorimetric reaction, optical density
(OD) at 450 nm was quantiﬁed by a microplate reader (Flex Station3,
722 A. Tlili et al. / Biochimica et Biophysica Acta 1832 (2013) 718–728Molecular Device), and OD readings were converted to concentra-
tions (μg/mL) on the basis of the standard curve obtained with apo
A-I standard preparation.
2.10. Data analysis
Statistical analysis was done with one-way analysis of variance
(ANOVA) followed by Student's unpaired t-test using Statview software.
For multiple pairwise comparisons, Bonferroni/Dunn test was used
when n>6, and Fisher's test when nb6 (n represents the number of
samples). The results are expressed asmedianswith interquartile ranges.
Data were considered signiﬁcant when p≤0.05. A p value of 0.06–0.10
was considered to indicate a strong statistical tendency due to the
small sample size. Correlations between plasma Hcy levels, plasma
PON1 activity, and plasma apo A-I levels or plasma Hcy levels and aortic
DYRK1A expressionwere determined by using Spearman's rank correla-
tion, as data were not normally distributed according to Shapiro–Wilk
test.
3. Results
3.1. Adenoviral vector “AdDYRK1A” gene transfer induces DYRK1A
overexpression in the liver of CBS-deﬁcient mice
To overexpress DYRK1A speciﬁcally in liver of CBS-deﬁcient mice,
we used an E1E3E4-deleted adenoviral vector [13], “AdDYRK1A”,
which was constructed to induce hepatocyte-speciﬁc expression of
DYRK1A (Fig. 1A). We injected “AdDYRK1A” in CBS-deﬁcient mice
(Cbs+/−), a murine model of hyperhomocysteinemia. Similar to a
previous report [6], DYRK1A protein levels was decreased in the
liver of Cbs+/− mice when compared with Cbs+/+ mice (Fig. 1B).
However, one week after injection of AdDYRK1A to Cbs+/− mice,
we observed an increase in DYRK1A protein levels when compared
with Cbs+/− mice (Fig. 1C). Because adenoviral expression of thera-
peutic gene is usually transient, we also analyzed the protein level
four weeks after injection and also found a signiﬁcant increase
(Fig. 1D). In order to verify the tissue speciﬁcity of DYRK1A over-
expression, we analyzed the DYRK1A protein levels in spleen of
Cbs+/− mice after injection of AdDYRK1A and found no difference
when compared with Cbs+/− mice (Fig. 1E). We did not observe
any morphological difference or perivascular ﬁbrosis in livers of
CBS-deﬁcient mice injected with adenoviral particles compared to
those of Cbs+/− mice (data not shown).
3.2. Hepatic DYRK1A overexpression reduces plasma Hcy levels in CBS-
deﬁcient mice
To determine the effect of DYRK1A overexpression on plasma Hcy
levels, we quantiﬁed plasma levels of Hcy in Cbs+/− mice with or
without Dyrk1a gene transfer. As expected, the Hcy levels in Cbs+/−
mice was higher than those of Cbs+/+ mice (Fig. 2A and B). Interest-
ingly, in Cbs+/− mice injected with AdDYRK1A, we observed the
same decrease in Hcy levels for male and female one week and four
weeks after injection (Fig. 2A and B).
3.3. Hepatic DYRK1A overexpression modulates Hcy metabolism
Because targeted overexpression of DYRK1A in liver normalized
the plasma Hcy levels of CBS-deﬁcient mice, we next studied hepatic
activities of the main enzymes implicated in Hcy metabolism. As Hcy
is lowered by its conversion into SAH, we ﬁrst assayed SAHH activity
in liver of mice. As previously found [7], SAHH activity was decreased
in the liver of Cbs+/− mice compared with Cbs+/+ mice (Fig. 2C).
After injection of AdDYRK1A, SAHH activity signiﬁcantly increased
one week (Fig. 2C) and four weeks after injection (data not shown).
Further, we determined the hepatic levels of SAM and SAH. Levelsof SAM in livers of Cbs+/+ mice and Cbs+/− mice expressing or lack-
ing AdDYRK1A were not different (Table 1). However, SAH levels
were higher in Cbs+/− mice than in Cbs+/+ mice (Table 1). After in-
jection of AdDYRK1A, the levels of SAH decreased (Table 1). Concom-
itantly, the SAM/SAH ratio signiﬁcantly decreased in Cbs+/− mice
compared with Cbs+/+ mice (Table 1). After injection of AdDYRK1A,
this ratio increased signiﬁcantly (Table 1).
We previously reported that, in a transgenic murine model
overexpressing DYRK1A [7], the increase in SAHH activity is not due
to an increase in SAHH expression, but occurs concomitantly with
an increase in NQO1 activity. NQO1 co-produces NAD+, which is a
cofactor of SAHH. Thus, here we assayed hepatic NQO1 activity. As
previously shown [7], NQO1 activity was lower in liver of Cbs+/−
mice compared with Cbs+/+ mice (Fig. 2D). After injection of
AdDYRK1A, we observed a signiﬁcant increase in NQO1 activity one
week (Fig. 2C) and four weeks after injection (data not shown).
Assays of hepatic CBS activity, revealed, as expected, signiﬁcantly
lower activity in Cbs+/− mice than in Cbs+/+ mice (Fig. 3A and B).
However, injection of AdDYRK1A (Cbs+/− AdDYRK1A) resulted in a
signiﬁcant increase in CBS activity after one week (Fig. 3A) and four
weeks (Fig. 3B). In order to show if the increase in CBS activity is
due to increased expressionof CBS,we analyzed the CBSprotein expres-
sion after injection of AdDYRK1A and found no difference when com-
pared with Cbs+/− mice after one week (data not shown) and four
weeks (Fig. 3C). As PLP, the metabolically active form of vitamin B6, is
the cofactor of CBS, we measured hepatic PLP concentration. We
found no difference in hepatic PLP concentration between Cbs+/−
mice and Cbs+/+mice (Fig. 3D). However, after injection of AdDYRK1A,
the hepatic PLP concentration was signiﬁcantly higher than in Cbs+/−
and Cbs+/+ mice (Fig. 3D).3.4. Hepatic DYRK1A overexpression rescues hepatic and plasma PON1
activity
Many factors predispose an individual to premature thromboembolic
and atherothrombotic events, including status of the antioxidant enzyme
PON1. PON1 is a high-density lipoprotein (HDL)-associated protein that
plays a major role in HDL-mediated protection against coronary artery
disease [29]. Moreover, PON1 is a phase I xenobiotic-metabolizing en-
zyme (XME) that acts like a thiolactonase, hydrolyzing Hcy-thiolactone
to Hcy [30]. We previously demonstrated that hepatic PON1 activity is
not only decreased in hyperhomocysteinemicmice, but is also negative-
ly correlated with plasma Hcy levels [21,31]. As expected, Cbs+/−mice
exhibited lower hepatic PON1 activity thanCbs+/+mice (Fig. 4A and B).
One week (Fig. 4A) and four weeks (Fig. 4B) after injection of
AdDYRK1A, we observed a signiﬁcant increase in hepatic PON1 activity.
Since PON1 is synthesized in the liver and is secreted into the serum, ac-
tivity of PON1 was also examined in plasma of mice. Cbs+/− mice had
signiﬁcantly lower plasma PON1 activity than Cbs+/+mice (Fig. 5A). In-
jection of AdDYRK1A resulted in a signiﬁcant increase in plasma PON1
activity (Fig. 5A).3.5. Hepatic DYRK1A overexpression increases plasma apo A-I levels
We also assayed plasma levels of apo A-I, the major protein asso-
ciated to HDL. Cbs+/− mice exhibited signiﬁcantly lower circulating
levels of apo A-I compared to Cbs+/+ mice (Fig. 5B). However, this
lower circulating level was not found at hepatic protein level
(Fig. 5C). AdDYRK1A injection resulted in a signiﬁcant increase in
plasma apo A-I levels (Fig. 5B), which is associated with increased he-
patic protein level (Fig. 5C). Further, a Spearman correlation test re-
vealed a signiﬁcant negative correlation between Hcy levels and
PON1 activity (ρ=−0.496, pb0.05) and between Hcy levels and
apo A-I levels (ρ=−0.506, pb0.05) (Fig. 5D).
Fig. 2. Effect of hepatic overexpression of DYRK1A on plasma Hcy levels and hepatic SAHH and NQO1 activities. Plasma Hcy levels in wild type (Cbs+/+) mice and CBS-deﬁcient
(Cbs+/−) mice one week (A) and four weeks (B) after injection or not of AdDYRK1A. Values are represented as means±SEM of concentration (μM). (C) Relative hepatic SAHH
and (D) NQO1 activities were determined in Cbs+/+ mice and Cbs+/− mice injected or uninjected with AdDYRK1A. Data were normalized to the mean of wild-type mice (Cbs+/+).
n=number of mice.
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PON1 and HDL exert protective effects on endothelial dysfunction,
which has been demonstrated in Cbs+/− mice [32]. Recent reports
demonstrated that hyperhomocysteinemia impaired endothelial func-
tion through compromised Akt/GSK3 signaling pathways [33,34]. We
ﬁrst analyzed the aortic expression of DYRK1A and found a decrease
in Cbs+/− mice. One week after injection of AdDYRK1A to Cbs+/−
mice (Cbs+/− AdDYRK1A), the decreased DYRK1A protein levels in
aorta of Cbs+/− mice were partially restored (Fig. 6A). Further, aSpearman correlation test revealed a signiﬁcant negative correlation
between plasma Hcy levels and aortic DYRK1A protein expression
(ρ=−0.748, pb0.0003). This result demonstrates that the increase in
aortic expression of DYRK1A obtained after hepatic DYRK1A over-
expression may be the result of Hcy-lowering. Given the link between
DYRK1A and PI3K/Akt pathway [9,35], we analyzed the activation of
Akt in aorta of mice. For this, we used RPPA technology which requires
only small amounts of samples and allows studying protein expression
and post-translational modiﬁcations in a large number of samples si-
multaneously. Commensurate with the decreased DYRK1A protein
Table 1
Hepatic SAM and SAH concentrations and SAM/SAH ratio in mice.
Data correspond to medians with interquartile ranges (25%; 75%).
Genotype
(n=number of mice)
SAM (nmol/g) SAH (nmol/g) SAM/SAH
Cbs+/+ (n=12) 67 (53; 77) 30 (27; 36) 2.3 (1.7; 2.6)
Cbs+/− (n=12) 72 (61; 83) 44 (36; 47)†† 1.8 (1.6; 2)⁎⁎
Cbs+/− AdDYRK1A (n=12) 68 (64; 82) 33 (30; 41)† 2 (1.9; 2.3)⁎
†† p≤0.005 compared to Cbs+/+.
† p≤0.07 compared to Cbs+/−.
⁎⁎ p≤0.02 compared to Cbs+/+.
⁎ p≤0.09 compared to Cbs+/−.
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aorta of Cbs+/− mice (Fig. 6B). This decreased activation can be
abolished after injection of AdDYRK1A to Cbs+/− mice (Fig. 6B). Akt
phosphorylates GSK3 alpha and beta on inhibitory serine residues 21
and 9 respectively. No difference was found for GSK3 protein expres-
sion. However, even if the 2-fold decrease of phosphorylated GSK3 in
aorta of Cbs+/− mice was not statistically signiﬁcant, the injection of
AdDYRK1A to Cbs+/− mice increased the phosphorylation of GSK3 on
serine residues (Fig. 6C). Activation of GSK3 alpha and beta can also
be modulated by phosphorylation of speciﬁc tyrosine residues 279Fig. 3. Effect of hepatic overexpression of DYRK1A on hepatic CBS activity. Relative hepatic
mice compared to wild type (Cbs+/+) and uninjected mice (Cbs+/−). (C) CBS protein expr
AdDYRK1A. Data were normalized to the mean of wild-type mice (Cbs+/+). (D) Hepatic PL
number of mice.and 216 respectively. However, no statistical difference was found be-
tween the three groups of mice (Fig. 6D), suggesting that it is mostly
the inactivation by Akt that is altered, rather than its activation through
other pathways.
4. Discussion
Elevated plasma Hcy levels is recognized as an important risk fac-
tor for vascular diseases [1,36]. Lowering Hcy levels could constitute a
good means of prevention of cardiovascular disease. Ebbing and col-
leagues analyzed data from two studies that included almost 7000
heart patients treated with B vitamins supplements or placebo for
an average of three and one-half years between 1998 and 2005 [37].
They found that B vitamins supplementation was associated with a
21% increased risk for cancer, a 38% increased risk for dying from
the disease, and an 18% increase in deaths from all causes. This ﬁnding
gives new evidence that B vitamins supplementation, taken in large
doses, may promote some cancers. Therefore, effective treatments
to reduce Hcy levels are needed, and gene therapy could provide a
useful approach.
We previously demonstrated a link between DYRK1A-related path-
ways andHcymetabolism [6,7].We implemented targeted gene therapy
to overexpress DYRK1A speciﬁcally in liver of hyperhomocysteinemic
mice. To demonstrate that this gene therapy could inﬂuence HcyCBS activity one week (A) and four weeks (B) after injection of AdDYRK1A in Cbs+/−
ession were determined in Cbs+/+ mice and Cbs+/− mice injected or uninjected with
P levels in Cbs+/+ mice and Cbs+/− mice injected or uninjected with AdDYRK1A. n=
Fig. 4. Effect of hepatic overexpression of DYRK1A on PON1 activity in liver of wild type
(Cbs+/+) mice and CBS-deﬁcient (Cbs+/−) mice one week (A) and four weeks (B) after
injection or not with AdDYRK1A. Data were normalized to the mean of wild-type mice
(Cbs+/+). n=number of mice.
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uninjected mice and found a decrease in plasma Hcy levels in
hyperhomocysteinemic mice injected with AdDYRK1A. We analyzed
the hepatic activities of twomajor enzymes involved in Hcy metabolism
inmice heterozygous for a targeted disruption of the Cbs gene (Cbs+/−).
Our previous work demonstrated that overexpression of DYRK1A in
transgenic mice has no effect on CBS activity [7]. However, those trans-
genic mice were homozygous for Cbs (Cbs+/+). In contrast, here we
report an increase in CBS activity in hyperhomocysteinemic mice
(Cbs+/−) injected with AdDYRK1A. The increased CBS activity could
not be attributed to increased protein levels, because we did not observe
a change in protein levels. Further, this result could not be explained by
hepatic SAM levels, which represent an allosteric activator of CBS, be-
causewe did not observe a change in SAM levels after injection of adeno-
viral particles. Therefore, wemeasured the hepatic PLP, themetabolically
active form of vitamin B6 and the cofactor of CBS.We found a signiﬁcant
increase in PLP in liver of hyperhomocysteinemic mice injected with
AdDYRK1A,which is consistentwith the increase in CBS activity. Howev-
er, no variation of nonphosphorylated pyridoxal (PL) level was found in
liver of hyperhomocysteinemicmice injectedwith AdDYRK1A compared
with non injected mice (data not shown). PLP is recycled from food and
from degraded PLP-dependent enzymes in a salvage pathway requiring
the action of pyridoxal kinase, pyridoxine 5′-phosphate oxidase and
phosphatases. The regulation of the salvage pathway is poorly under-
stood and represent a very challenging research ﬁeld. The role of
DYRK1A on this salvage pathway remains to be elucidated.
We show that SAHH and NQO1 activities are increased in
hyperhomocysteinemic mice injected with AdDYRK1A. Transgenicmice overexpressing DYRK1A have an increased activity of the SAHH
enzyme [7], and increased NQO1 gene expression and activity through
a nuclear-E2-related factor-2 (Nrf2) mechanism [38]. Increased activity
of NQO1 is followed by an increase of a by-product of the enzyme reac-
tion, NAD+, which is a cofactor of SAHH [39]. Thus, the decrease in Hcy
levels after overexpression of DYRK1A is a consequence of increased
CBS activity, but also of increased SAHH activity induced by increased
NQO1 activity. Plasma Hcy levels can therefore be modulated by he-
patic Hcy metabolism in hyperhomocysteinemic mice. Speciﬁc he-
patic overexpression of CBS also results in a decrease in plasma Hcy
levels [18]. Targeted expression through injection of AdDYRK1A
resulted in decreased SAH and increased SAM/SAH ratio in liver of
hyperhomocysteinemic mice. The process of Hcy synthesis, called
the activated methyl group pathway, generates methyl groups used
in numerous metabolic processes via the adenosylated compounds
SAM and SAH, the key metabolites considered to be indicators of
DNA methylation status. The ratio of SAM/SAH is frequently used as
an indicator of cellular methylation capacity [40]. A decrease in this
ratio, as found in liver of hyperhomocysteinemicmice, predicts reduced
cellular methylation potential and can be alleviated by injection of ade-
novirus overexpressing DYRK1A. Moreover, some studies have shown
that a high plasma SAH levels is a strong risk factor of cardiovascular
diseases [41]. As such, the decreased Hcy and SAH levels after hepatic
overexpression of DYRK1A could help to prevent cardiovascular dis-
eases linked to hyperhomocysteinemia.
Hyperhomocysteinemic mice exhibit decreased hepatic and plasma
activities of PON1 [21,32], and plasma apo A-I levels. Signiﬁcantly de-
creased plasma and hepatic protein levels of apo A-I have been
observed in mice that are heterozygous for MTHFR [42], which empha-
sizes the role of hyperhomocysteinemia on plasma apo A-I level. How-
ever, the decreased hepatic protein level was not found statistically
signiﬁcant in mice that are heterozygous for CBS [42]. Speciﬁc hepatic
overexpression of DYRK1A corrected the decreased hepatic and plasma
PON1 activities, and the decreased plasma apo A-I level which is associ-
ated with increased hepatic protein level. We also found a negative
correlation between plasma Hcy and apo A-I levels, as previously dem-
onstrated [42], and between plasmaHcy levels and PON1 activity. PON1
is a phase I XME synthesized by the liver with antioxidant proper-
ties [29] and a thiolactonase, hydrolyzing Hcy-thiolactone to Hcy [31].
We have previously shown that the activation of NQO1 expression, a
phase II XME, by DYRK1A, depends on Nrf2 but is independent of the
arylhydrocarbon receptor (AhR) [38]. However, PON1 is not regulated
by the Nrf2 signaling pathway [43], but by the AhR pathway [44]. We
previously found that a chronic supplementation of polyphenolic com-
pounds could decrease plasma Hcy levels and restored the hepatic and
plasma-decreased PON1 activity induced by hyperhomocysteinemia
[32]. Taken together, our results demonstrate that the increase in hepat-
ic and plasma PON1 activity obtained after hepatic overexpression of
DYRK1A correlateswithHcy-lowering. PON1 andHDL exert potent pro-
tective effects, including the prevention and correction of endothelial
dysfunction [45,46], which has been also demonstrated after Hcy-
lowering by speciﬁc hepatic gene transfer of CBS [18]. Commensurate
with the decreased PON1 activity and apo A-I levels in plasma of
Cbs+/−mice, we found aortic PI3K/Akt inhibition and GSK3 activation,
associated with a decreased aortic DYRK1A protein level. The negative
correlation between plasma Hcy levels and aortic DYRK1A protein ex-
pression demonstrates that the increase in aortic DYRK1A protein ex-
pression obtained after hepatic overexpression of DYRK1A may be the
result ofHcy-lowering. Recent results found that hyperhomocysteinemia
also inhibited the phosphorylation of Akt in liver of mice [47,48], which
could be associated with the decreased DYRK1A protein level [6].
Targeted hepatic expression through injection of AdDYRK1A resulted
in plasma Hcy-lowering, and then PI3K/Akt activation and GSK3 inhibi-
tion in aorta of mice, which can prevent endothelial dysfunction. Al-
though anti-apoptotic properties of DYRK1A could be associated with
tumorigenic effects, both Ts65Dn mouse models of Down syndrome
Fig. 5. Effect of hepatic overexpression of DYRK1A on plasma PON1 activity and plasma and hepatic apo A-I levels. (A) Relative plasma PON1 activity, (B) plasma apo A-I and (C) hepatic
apo A-I levels were determined in Cbs+/+ mice and Cbs+/−mice injected or uninjected with AdDYRK1A. Data were normalized to the mean of wild-type mice (Cbs+/+). n=number of
mice. (D) Correlations of relative PON1 activity and apo A-I levels with Hcy levels in plasma of Cbs+/+ mice and Cbs+/−mice injected or uninjected with AdDYRK1A. Increasing levels of
Hcy and PON1 activity or apo A-I levels in plasma were negatively correlated at pb0.04 and pb0.03 with a ρ=−0.503 and ρ=−0.574, respectively. For correlations test, we used only
female mice.
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tion in response to vascular endothelial growth factor (VEGF) [49]. This
effect has been attributed to dysregulation of VEGF-calcineurin-NFAT
signaling through increased expression of DSCR1 and DYRK1A. Another
potential effect of the increase of DYRK1A can be hypothesized froma re-
port showing that the expression of Nrf2 and NQO1 were suppressed in
tumorigenic cells in prostate cancer of TRAMP mice [50] although we
have shown that increased expression of Dyrk1a is associatedwith an in-
crease of Nrf2 and NQO1.
Recentwork has shown thatDyrk1a overexpression can be oncogen-
ic causing acute megakaryoblastic leukemia through dysregulation of
nuclear factor of activated T cells (NFAT) activation in Down syndrome
model of mice. However, given that calcineurin/NFAT pathway inhibi-
tion has been implicated in the decreased tumor incidence in adults
with Down syndrome, the authors also demonstrated that the same
pathway can be both proleukemic in children and antitumorigenic in
adults [51]. In light of these results, a limitation of an AdDYRK1A inter-
vention might be the age of patients; it would be safer to restrict this
strategy to adult patients.
5. Conclusion
Our data provide preliminary evidence supporting the potential
use of this gene delivery as a therapy for the treatment of hyper-
homocysteinemia. The positive effect on plasma Hcy, plasma apoA-1levels, plasmaPON1activity and aortic Akt/GSK3 signaling pathwaydem-
onstrates that this gene therapy can constitute a useful approach for pre-
vention of cardiovascular diseases linked to hyperhomocysteinemia. This
approach might also beneﬁt other disease [52–54] in which hepatic Hcy
metabolism is affected and vascular alterations are prevalent.Acknowledgements
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Fig. 6. Effect of hepatic overexpression of DYRK1A on aortic DYRK1A, phospho-Akt and phospho-GSK3 levels. (A) DYRK1A protein level in aorta of wild type (Cbs+/+) mice and
Cbs+/−mice after one week injection or not with AdDYRK1A determined by Slot blotting. Values were obtained by normalization of images from DYRK1A to total proteins colored
with Ponceau-S. Phosphorylation of Akt (B), GSK3 alpha and beta on ser 21 and 9 (C) and tyr 279 and 216 (D) determined by RPPA. Relative protein expression was determined by
normalization from P-Akt or P-GSK3 with that of total Akt or GSK3. Data were normalized to the mean of wild-type mice (Cbs+/+). n=number of mice.
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